FDA Approved: SOLIQUA 100/33 — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for SOLIQUA 100/33, a fixed-ratio combination of insulin glargine and lixisenatide, developed by Sanofi-Aventis U.S. LLC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SOLIQUA 100/33 (INSULIN GLARGINE AND LIXISENATIDE)

Snippet

SUPPL AP for SOLIQUA 100/33 (INSULIN GLARGINE AND LIXISENATIDE)